MedPath

Sintilimab

Generic Name
Sintilimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2072873-06-2
Unique Ingredient Identifier
8FU7FQ8UPK
Associated Conditions
-
Associated Therapies
-

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Phase 2
Conditions
Sarcoma, Soft Tissue
Interventions
First Posted Date
2020-04-22
Last Posted Date
2020-07-14
Lead Sponsor
Fudan University
Target Recruit Count
45
Registration Number
NCT04356872
Locations
🇨🇳

Fudan University, Cancer Hospital, Shanghai, Shanghai, China

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Phase 2
Active, not recruiting
Conditions
Colorectal Cancer Stage II
Colorectal Cancer Stage III
Interventions
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Sintilimab
Procedure: total mesorectal excision
Radiation: radiotherapy
Other: Watch and wait
First Posted Date
2020-03-11
Last Posted Date
2023-02-01
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
195
Registration Number
NCT04304209
Locations
🇨🇳

Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Phase 2
Recruiting
Conditions
Cutaneous T-cell Lymphoma
Interventions
First Posted Date
2020-03-05
Last Posted Date
2020-03-05
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
52
Registration Number
NCT04296786
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma

Phase 2
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Sintilimab
Combination Product: TACE
First Posted Date
2020-03-05
Last Posted Date
2024-01-19
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT04297280
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Phase 2
Conditions
Extranodal NK/T-cell Lymphoma
Interventions
First Posted Date
2020-02-21
Last Posted Date
2020-05-07
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
20
Registration Number
NCT04279379
Locations
🇨🇳

Beijing Tongren Hospital, Beijing, China

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Phase 2
Active, not recruiting
Conditions
Gastric Cancer Stage IV
Interventions
First Posted Date
2020-02-13
Last Posted Date
2023-07-06
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
47
Registration Number
NCT04267549
Locations
🇨🇳

Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Phase 2
Conditions
Metastatic Gastric Cancer
Stomach Adenocarcinoma
Locally Advanced Unresectable Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Interventions
First Posted Date
2020-02-11
Last Posted Date
2020-02-11
Lead Sponsor
Sichuan University
Target Recruit Count
36
Registration Number
NCT04263870
Locations
🇨🇳

West China Hospital, Sichuan University, Chengdu, Sichuan, China

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Phase 2
Conditions
Nsclc
Interventions
First Posted Date
2020-02-05
Last Posted Date
2020-02-05
Lead Sponsor
Guangdong Association of Clinical Trials
Target Recruit Count
20
Registration Number
NCT04252365

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

Phase 2
Conditions
NK/T Cell Lymphoma Nos
Interventions
First Posted Date
2020-01-18
Last Posted Date
2020-05-07
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
20
Registration Number
NCT04231370
Locations
🇨🇳

Beijing Tongren Hospital, Beijing, China

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Phase 1
Active, not recruiting
Conditions
Hepatic Carcinoma
Interventions
Drug: Sintilimab
Procedure: Microwave Ablation
Procedure: TACE
First Posted Date
2020-01-07
Last Posted Date
2024-08-01
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
45
Registration Number
NCT04220944
Locations
🇨🇳

Department of Interventional Radiology, Zhongshan Hospital, Fudan University., Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath